GSK will be hoping the device will help it ... and payers are demanding more from its next generation treatments Breo and Anoro Ellipta. “Digital innovations, like sensor technologies, will ...
investigating whether the triple therapy can reduce rate of exacerbations compared with two dual therapies from GSK’s portfolio: Relvar Ellipta (fluticasone+vilanterol) and Anoro Ellipta ...
Zacks.com on MSN10d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
Hosted on MSN1y
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 GuidanceGSK plc GSK reported adjusted earnings of 72 ... This upside was driven by solid sales growth of respiratory drugs, Anoro Ellipta, Breo Ellipta and Trelegy Ellipta and the continued post-pandemic ...
Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care ...
Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback